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Abstract 
The dopamine hypothesis is the longest standing pathoaetiological theory of 
schizophrenia. As it was initially based on indirect evidence and findings in patients 
with established schizophrenia it was unclear what role dopamine played in the onset 
of the disorder. However, recent studies in people at risk of schizophrenia have 
found elevated striatal dopamine synthesis capacity, and increased dopamine 
release to stress. Furthermore, striatal dopamine changes have been linked to 
altered cortical function during cognitive tasks, in-line with preclinical evidence that a 
circuit involving cortical projections to the striatum and midbrain may underlie the 
striatal dopamine changes. Other studies have shown that a number of 
environmental risk factors for schizophrenia, such as social isolation and childhood 
trauma, also impact on presynaptic dopaminergic function.  
 
Advances in preclinical work and genetics have begun to unravel the molecular 
architecture linking dopamine, psychosis and psychosocial stress. Included among 
the many genes associated with risk of schizophrenia, are the gene encoding the 
DRD2 receptor and those involved in the up-stream regulation of dopaminergic 
synthesis, through glutamatergic and gamma-aminobutyric acid (GABA)-ergic 
pathways. A number of these pathways are also linked to the stress response. We 
review these new lines of evidence and present a model of how genes and 
environmental factors may sensitise the dopamine system so that it is vulnerable to 
acute stress, leading to progressive dysregulation and the onset of psychosis. 
Finally, we consider the implications for rational drug development, in particular 
regionally selective dopaminergic modulation, and the potential of genetic factors to 
stratify patients. 
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Introduction  
The dopamine hypothesis has been the leading pathoaetiological theory of 
schizophrenia for over four decades (1–3). Our understanding of schizophrenia has 
progressed through advances in neuroimaging, epidemiology, and research into the 
prodromal phase that predates the onset of the disorder in many patients. Meanwhile 
the role of genetic and environmental risk factors for schizophrenia has been 
clarified. Studies of how these risk factors impact on the dopamine system, coupled 
with longitudinal studies during the prodrome allow for a more refined understanding 
of what leads to the onset of psychosis. This review synthesizes the evidence on the 
nature of dopaminergic abnormalities in schizophrenia and its prodrome, and how 
risk factors lead to illness, before considering the implications for treatment and 
prevention. 
 
The origins of the dopamine hypothesis 
The origins of the dopamine hypothesis lie in two lines of evidence. First, clinical 
studies established that dopaminergic agonists, and stimulants could induce 
psychosis in healthy individuals, and worsen psychosis in patients with schizophrenia 
(4; 5). Second, was the discovery that antipsychotic drugs affect the dopamine 
system (6). Later, the potency of antipsychotics was linked to their affinity for 
dopamine D2 receptors - linking molecular action to clinical phenotype (7). 
 
Post-mortem studies provided the first direct evidence for dopaminergic dysfunction 
in the brain and its anatomical localization. These showed elevated levels of 
dopamine, its metabolites, and its receptors in the striata of people with 
schizophrenia (8; 9). However, the studies were of patients who had received 
antipsychotics. Consequently, it was not clear if the dysfunction was linked to onset, 
or an end-stage effect of the disorder, or indeed a consequence of antipsychotics.  
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In vivo imaging of dopamine in schizophrenia 
The development of positron emission tomography (PET) and single photon 
computed tomography (SPECT) specific radiotracers enabled the dopamine system 
to be studied in vivo with high molecular specificity (10). 
 
Studies of the dopamine transporter (DAT) (3; 11) and vesicular monoamine 
transporter (VMAT) (12; 13) availability in the striatum show no abnormality either in 
chronic patients or in drug naïve first episode patients. Likewise, while meta-analysis 
has shown that there may be a small elevation in dopamine D2/3 receptor availability 
in schizophrenia, it is not reliably seen in antipsychotic-naive patients (3).  
 
Presynaptic  dopaminergic function can be indexed using either radiolabelled l-
dihydroxyphenylalanine (l-dopa), or one can measure the change in radiotracer 
binding to D2/3 receptors following a challenge designed to stimulate dopamine 
release.  A significant elevation was reported in a meta-analysis of presynaptic 
dopaminergic function using these techniques (cohen’s d=0.8) (3), and subsequent 
studies have reported even larger effect sizes (14–16). Furthermore baseline 
occupancy of D2/3 receptors by dopamine has also been found to be elevated, 
indicating higher synaptic dopamine levels at rest (17; 18). Striatal dopamine release 
and baseline dopamine levels are closely correlated in schizophrenia (19), 
suggesting that the same abnormality underlies both.  
 
While the striatum has received the greatest attention in PET studies, it has long 
been hypothesized that alterations in the dopamine system extend to additional brain 
regions (20).  Dopaminergic hypofunction in the dorsolateral prefrontal cortex 
(DLPFC) has been proposed to account for negative and cognitive symptoms. 
Recently people with schizophrenia have been found to show reduced dopamine 
release in the DLPFC following amphetamine challenge, and this release was shown 
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to correlate with DLPFC activation during a working memory task (21). Meta-analysis 
of studies that have examined extra-striatal receptor densities indicate there are 
unlikely to be large differences in D2/3 receptors and transporters in the regions 
studied, whilst the D1 findings are inconsistent, potentially due to the effects of prior 
antipsychotic treatment (22). 
 
 
In vivo imaging of dopamine in people at clinical high risk of psychosis 
The use of structured clinical assessments has made it possible to identify cohorts 
with prodromal symptoms, in which the risk of transition to psychosis can be as high 
as 40%, though recent studies have reported lower rates (23). Various studies have 
suggested that dopaminergic abnormalities exist in people at clinical high risk (CHR) 
of psychosis. Antipsychotic treatment trials have demonstrated efficacy of dopamine 
blockade in reducing prodromal-type symptom severity (24; 25), and elevations in 
peripheral dopamine metabolites have been observed in CHR cohorts (26). 
However, these findings cannot tell us directly about central dopaminergic 
dysfunction, in this respect imaging has been particularly useful.  
 
Three studies have examined D2/3 receptor density in CHR populations; all showing 
no differences between groups (see table 1) (27–29). In two studies this could 
conceivably have been due to increased synaptic dopamine masking a difference in 
receptor densities (27; 28). One study, however, addressed this with a dopamine 
depletion paradigm, and showed no significant differences (29). 
 
Presynaptic dopaminergic function 
Initial research showed that dopamine synthesis capacity was raised in CHR 
individuals (30), and positively associated with the severity of prodromal-type 
symptoms (see table 1). This has subsequently been replicated (31), and found to be 
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specific to prodromal individuals who progress to psychosis (32). Furthermore, re-
scanning subjects as they developed psychosis showed that dopamine synthesis 
capacity increases further with the development of acute psychosis (33). Additionally, 
greater dopamine release was found following psychological stress in CHR 
individuals compared to controls (15). The dopamine dysfunction was localized to the 
dorsal striatum, particularly areas functionally linked with the prefrontal cortex (PFC), 
and this was associated with altered function in frontal and temporal cortical regions 
(34; 35). However, in contrast to findings in schizophrenia(17–19), dopamine 
depletion did not reveal differences in baseline synaptic levels of dopamine between 
at risk individuals and healthy controls, although at risk individuals reported 
symptomatic improvement following depletion (29). These findings indicate that 
whilst dopaminergic functioning is already dysregulated in those prodromal people 
who later progress to schizophrenia, it is not as marked as in patients with the 
disorder, and there is further dysregulation from the prodrome to psychosis. 
 
Psychosocial stress and schizophrenia  
In addition to genetic factors, neurodevelopmental hazards (36) and cannabis use 
(37); chronic psychosocial stressors including childhood adversity (38), 
migration/ethnic minority status (39), and urbanicity (40), have become accepted as 
increasing the risk of schizophrenia. Furthermore, acute stress plays a role in 
triggering psychotic symptoms (41; 42), and impaired stress tolerance is associated 
with prodromal symptoms (43).  
 
The effects of psychosocial stress on dopamine  
Animal studies consistently show that acute stressors (psychosocial and physical) 
lead to cortical dopamine release, and that this dampens striatal dopamine release 
(53; 54). Dopaminergic inhibition of cortical glutamatergic neurons projecting to the 
striatum and midbrain is one pathway that potentially accounts for this (see figure 1)  
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(55). The effects of chronic stress on the dopamine system vary by brain region and 
depend on the nature of the stress. In animals exposed to chronic stress, baseline 
levels of frontal dopaminergic activity are reduced, but responses to acute stress are 
elevated (56; 57). With regard to the mesostriatal system, some studies suggest that 
chronic stress reduces dopaminergic responses to later activating stimuli (58–60), 
while others show increased release in response to subsequent amphetamine (61; 
62). It seems that prior exposure to chronic or inescapable stressors may down 
regulate the system, while intermittent and escapable stress is more likely to have a 
sensitising effect (60; 63). 
 
Studies of CHR individuals, individuals with schizophrenia and first degree relatives 
have shown that they produce a greater peripheral homovanillic acid response to 
stress (26; 64; 65). Two healthy volunteer PET studies demonstrated more 
widespread cortical displacement of a D2/3 radiotracer during a stress task relative to 
a control task (66; 67) (see table 3). In one of these a positive correlation between 
childhood adversity and extent of cortical dopamine release was observed (68). The 
authors interpret this as potentially a resilience promoting mechanism. A study of first 
degree relatives of individuals with schizophrenia showed less widespread cortical 
dopaminergic response to stress relative to healthy controls (69), and this was 
related to subjective stress and increased psychotic-like reactions to stress (70).  
Blunted cortical release of dopamine to amphetamine has been found in 
schizophrenia (21). However, a study of individuals with schizophrenia found no 
difference in the regional extent of cortical dopaminergic response to stress 
compared to controls, although the participants in this study had low symptom 
severity (71). 
 
In the striatum, greater striatal dopamine release in response to acute social stress 
has been observed both in individuals at risk for psychosis (15; 76) and those with 
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schizophrenia (28).  Additionally, greater dopamine synthesis capacity (72), and 
release (in response to stress (73) and amphetamine (74)) has been found in 
individuals exposed to childhood adversity. Greater dopamine release to 
amphetamine was also seen in people  exposed to social isolation by virtue of 
hearing impairment (75).   
 
Molecular mechanisms linking dopamine, stress and psychosis 
A diathesis-stress model of schizophrenia proposes that the illness develops due to 
stress exposure acting on a pre-existing vulnerability (secondary to genetic factors or 
early environmental insults) (77; 78). However, the molecular architecture underlying 
this relationship remains unclear. Genetic studies provide a means of identifying 
potential molecular mechanisms that underlie the disorder without the risk of 
confounding by treatment or other factors.  
 
The genetics of schizophrenia and the dopamine system 
Amongst the 108 loci associated with schizophrenia in the largest scale GWAS to 
date, one was for the dopamine receptor 2 (D2) (79). Furthermore a recent 
systematic pathway analysis of the Psychiatric Genetics Consortium’s enlarged 
sample (PGC2) GWAS findings identified the top pathway for genes associated with 
schizophrenia as being that for dopaminergic synapse (80)  (Holmans P, personal 
communication). However, this is a large set of genes, which includes many involved 
more widely in neurotransmission and signalling, that impinge indirectly on 
dopaminergic transmission. For example both AMPA and NMDA receptor subtypes 
are included. A more recent analysis of the PGC2 GWAS data focussed on a set of 
11 genes more directly related to dopamine synthesis, metabolism and 
neurotransmission (81). This confirmed the association with SNPs in the vicinity of 
DRD2, but found no evidence for enrichment in the other genes, or in the set as a 
whole.  While these results do not add further support to the hypothesis that direct 
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effects on dopaminergic neurotransmission partially mediate genetic susceptibility to 
schizophrenia, they do not exclude a role for rare variants in core dopaminergic 
genes, or other mutational mechanisms such as repeat sequences that are poorly 
tagged in GWAS studies. It remains to be determined whether there is enrichment of 
genetic signal in other restricted gene sets relating to dopaminergic function, such as 
signal transduction and post-synaptic signalling.  It is also possible that dopaminergic 
genes play a more prominent role in clinical subsets of schizophrenia or in cases 
defined on the basis of drug response.   
 
The finding from PGC2 that SNPs at the DRD2 locus are associated with 
schizophrenia is of great potential relevance to understanding the role of 
dopaminergic neurotransmission in the disorder, and to identifying upstream and 
downstream mechanisms. However, it is possible that the associated SNP(s) are 
modulating the function of another gene either in cis or trans rather than DRD2 itself. 
There is thus a pressing need to determine how, where and at what developmental 
stage(s) this association impacts mechanistically on gene function. As well as 
confirming an aetiological role for dopamine dysfunction this might be expected to 
provide important new insights into the nature of dopamine system dysfunction in the 
disorder. 
 
Genes involved in dopaminergic neurotransmission downstream of the synapse have 
also been linked to an increased risk of schizophrenia. Post-synaptic dopamine 
neurotransmission includes kinases such as the serine-threonine kinase Akt. Akt3 
was associated with schizophrenia in the GWAS described above (79), while Akt1 
has been linked to schizophrenia in other studies (82; 83). Functional changes to 
post-synaptic signal transduction could conceivably alter regulatory feedback onto 
presynaptic dopaminergic neurons (84).  
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The genetics of psychosocial stress and the dopamine system 
Gene-environment studies using epidemiological approaches have demonstrated 
interactions between genetic and psychosocial risk factors for schizophrenia (85–87). 
The importance of environmental effects may explain why the dopamine imaging 
evidence is inconsistent in people who may carry genetic risk for schizophrenia, such 
as relatives of people with schizophrenia, both in terms of dopamine synthesis 
capacity (88; 89), and D1 (90) and D2 (91; 92) receptor availability (see table 2). 
Below we discuss genes that may mediate the relationship between stress exposure, 
dopaminergic functioning, and psychosis. 
 
Catechol-O-methyltransferase (COMT, a major dopamine catabolic enzymes) was 
implicated in early candidate gene studies, and is located within one of the strongest 
genetic risk factors for schizophrenia, a 1.5-3 Mb deletion at 22q.11.2. (93) COMT 
contains a functional polymorphism involving a valine (Val) to methionine (Met) 
substitution. The functional consequences of variation at this locus have been widely 
studied, but it should be born in mind that there was no evidence for association of 
the Val/Met variant with schizophrenia in the PGC2 (95). The Met allele is associated 
with reduced catabolic activity, and is linked to greater tonic and reduced phasic 
striatal dopaminergic transmission (96). In the cortex, a PET study investigating D1 
receptor density suggested that the Val allele was associated with lower levels of 
baseline dopamine( 99) (although no association was observed in a study of cortical 
D2 receptors) (98). A study examining stress induced cortical dopamine release 
suggested the Met allele was associated with reduced release (and a greater 
subjective stress response) (99).  
 
Stress induced catecholamine release can impair working memory (100). During 
acute stress, Met homozygotes show impairments in working memory performance 
and reduced PFC activation, while Val carriers show the opposite effects (101; 102). 
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This has been interpreted in terms of the inverted-U relationship between dopamine 
levels and cognitive function – the greater level of dopaminergic function at baseline 
in Met carriers means an increase impairs performance; whereas in the case of the 
Val allele, the increase is beneficial. 
 
In terms of chronic stress, Met homozygosity has been associated with a negative 
relationship between the number of stressful life events and hippocampal volume, 
while the opposite relationship is seen for Val homozgosity (103). In Val 
homozygotes increased lifetime stress was found to correlate with reduced 
methylation which in turn correlated with poorer working memory performance (104). 
The Val allele has a methylation site absent on the Met allele, it may be that 
increased methylation in Val homozygotes, leads to reduced gene expression, 
leading to individuals’ COMT having activity similar to a Met carrier.   
 
Similarly to COMT, brain-derived neurotrophic factor (BDNF) has a Val/Met 
functional polymorphism. A  PET study of BDNF polymorphisms showed that Met 
carriers had greater striatal dopamine release in the context of a pain stressor (105).  
Consistent with this finding, the Met allele has been associated with increased stress 
induced paranoia in healthy individuals (106). 
 
The expression and functioning of DRD2 is affected by both genetic polymorphisms 
and environmental factors. In a healthy volunteer study, heterozygotes for a DRD2 
SNP showed greater stress induced striatal dopamine release compared to 
homozygotes (107). An animal study showed increased D2 receptor density in the 
nucleus accumbens following early life maternal deprivation, but only in 
heterozygotes for a separate DRD2 polymorphism (108). 
 
In contrast to studies of synaptic and post-synaptic dopamine genes, there have 
 12 
been fewer for presynaptic genes, such as those for synthetic enzymes and proteins 
regulating presynaptic storage of dopamine. Whilst the few published studies are 
inconsistent (109–111), this is an area that warrants investigation given the imaging 
findings. Disrupted In Schizophrenia (DISC1) is involved in a pathway that regulates 
presynaptic dopaminergic function, is one of the best studied loci linked to an 
increased risk of schizophrenia (112), and displays abnormal expression in induced 
pluripotent stem cells (IPSCs) from individuals with schizophrenia (113).  Animal 
models have demonstrated that alterations in DISC1 can lead to both impaired 
development of mesocortical dopaminergic neurons, and increased amphetamine 
induced striatal dopamine release (114). Adolescent isolation stress has been shown 
to lead to behavioural abnormalities only in mice with DISC1 mutations, secondary to 
glucocorticoid mediated changes to the functioning of mesocortical dopaminergic 
pathways (115). DISC1 is also involved in anchoring phosphodiesterase 4A (PDE4A) 
next to the spine apparatus (116). The gene coding for PDE4A has also been linked 
to schizophrenia (117), and both DISC and PDE4A together modulate modulate 
stress signalling pathways. Impairment of DISC1 reduces its ability to anchor PDE4A 
and this in turn leads to a disinhibition of the stress response and accompanying 
PFC impairment (122).  
 
The relationship between dopamine and other neurotransmitters 
DISC1 is also involved in glutamatergic neurotransmission (112). Furthermore, both 
GWAS and copy number variant (CNV) studies have implicated other genes involved 
in glutamatergic neurotransmission, including N-Methyl-D-Aspartate (NMDA) and 
other glutamatergic receptors (123). There is evidence that NMDA hypofunction 
disrupts the inhibitory/excitatory equilibrium at interneurons and thereby leads to 
increased dopamine release (see figure 1 and Abi-Dargham et al also in this issue) 
(124–126). Neurons derived from IPSCs from patients with schizophrenia show 
greater basal and activity dependent dopamine secretion (127), as well as reduced 
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glutamate receptor and altered DISC1 expression (113). Glutamatergic 
neurotransmission is also mediates the effects of both acute and chronic stress 
(128). 
 
Recent evidence from over 11,000 patients with schizophrenia and 16,000 controls 
has also shown an enrichment of CNVs involving glutamatergic and GABAergic 
systems (129). These systems have excitatory and inhibitory effects respectively on 
dopaminergic function, suggesting that the genetic variants in these systems may 
alter the regulation of dopamine in schizophrenia. Thus it is plausible that a number 
of the genetic risk variants in upstream pathways modulate dopamine function.  
Future studies must first clarify the molecular pathways, and links between the 
genetic variants and effects on glutamatergic and GABAergic neuronal function, 
before the link to down-stream dopaminergic effects can be tested. 
 
 
Integrating the imaging, stress and genetic findings 
Collectively the imaging findings identify increased striatal presynaptic synthesis and 
release of dopamine, as the major locus of dopaminergic dysfunction in 
schizophrenia. Furthermore, it appears this dysfunction is also present in the 
prodrome, and linked to the clinical development of the disorder. This suggests that 
presynaptic striatal dopamine dysfunction plays a causal role in the development of 
psychosis. 
 
The genetic findings have not implicated genes directly involved in determining 
dopamine synthesis or release, but instead point to up-stream and down-stream 
pathways linked to the dopamine system. A number of the genetic risk factors 
converge on up-stream pathways, particularly those involving glutamatergic systems. 
As glutamatergic projections to the striatum and midbrain regulate presynaptic 
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dopaminergic function, genetic variants affecting glutamatergic function could alter 
the regulation of dopaminergic function. The net effect of this may be to reduce the 
homeostatic control of midbrain dopamine neurons, making them more vulnerable to 
sensitisation by the socio-developmental risk factors described above. In addition, a 
number of other genetic risk factors impact on dopamine receptors and post-synaptic 
signal transduction pathways, to modulate post-synaptic dopaminergic 
neurotransmission. The net effect of this may be to increase the sensitivity of the 
medium spiny neurons in the striatum to dopamine. This suggests that the genetic 
risk factors for schizophrenia may play two roles: the up-stream factors render the 
dopamine neurons vulnerable to dysregulation, whilst the down-stream factors 
amplify the effects of dysregulation.  
 
We have also discussed the effect of stress on the cortico-striatal dopamine system, 
and how genetic and environmental influences moderate this. Recent studies in 
patients with schizophrenia and their relatives show blunted cortical dopamine 
release to a challenge. This is likely to reduce the inhibition of meso-striatal 
dopamine release, and result in augmented stress induced striatal release of 
dopamine. The preclinical findings suggest that this involves glutamatergic 
projections to the striatum and midbrain acting on GABAergic interneurons, both of 
which may hypofunctional due to genetic risk variants affecting glutamatergic and 
GABAergic receptors linked to schizophrenia. Thus blunted cortical dopaminergic 
release to stress coupled with impaired glutamatergic regulation of dopamine 
neurons may act on a sensitized mesostriatal dopamine system to result in increased 
striatal dopamine dysfunction (see figure 2).  
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Treatment Implications 
Current pharmacological treatments for schizophrenia primarily operate as post-
synaptic D2/3 receptor antagonists (130). Whilst these bring symptomatic relief, they 
do not target the underlying pathophysiology - even patients who have responded to 
antipsychotics show elevated striatal dopamine synthesis capacity (131). 
Furthermore, antipsychotics show limited effectiveness in targeting negative and 
cognitive symptoms.  
 
Given the evidence that cognitive symptoms are linked to cortical hypofunction, 
including reduced cortical dopamine release, it is unsurprising that dopamine 
blockade does not help these symptoms. Furthermore, anti-dopaminergic blockade 
of ventral striatal regions may impair motivation and affective processing, and so 
worsen negative symptoms. A clear implication is that we need regionally selective 
treatments: dampening dopamine neurotransmission in the striatum, specifically the 
dorsal striatum where dopamine elevation is most marked, and augmenting it in the 
cortex. Animal studies suggest that some existing pharmacological agents such as 
mirtazapine may be able to selectively augment cortical dopamine transmission. 
Interestingly, mirtazapine is used as a treatment in stress related disorders (133), 
and it may be an effective adjunctive treatment for negative symptoms in 
schizophrenia (134). 
  
Up-stream and down-stream genetic factors may have implications for treatment. 
Putatively people with a high loading for up-stream genetic risk might show marked 
presynaptic dopamine dysfunction, whilst those with a high loading for post-synaptic 
risk might show minimal presynaptic dysfunction but would be highly sensitive to the 
effects of even small amounts of dopamine release. There is evidence that a sub-
group of individuals with schizophrenia and co-morbid substance dependence (135) 
or cannabis-induced psychotic symptoms (49) do not show increased dopamine 
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synthesis or release, and that sensitivity to the psychotogenic effects of cannabis is 
linked to these down-stream genetic risk factors. Individuals predominantly affected 
by down-stream factors might be more sensitive to the side-effects of D2/3 receptor 
blockade (136), but might tolerate partial agonists better.  
 
 
Limitations 
A number of the aspects of the model described await testing. It remains to be 
established if genetic and environmental factors interact to sensitize the dopamine 
system, if there is blunted cortical dopamine release in the prodrome, and if blunted 
cortical dopaminergic function leads to striatal hyperdopaminergia. Moreover, whilst 
preclinical evidence supports the glutamatergic circuit regulating dopamine, the 
specifics remain to be tested in humans and reverse causality is yet to be excluded. 
 
A number of the COMT findings are difficult to integrate into the model.  There is no 
evidence from GWAS supporting association with SNPs in COMT.  In healthy 
individuals, the Val allele is associated with increased social stress induced paranoia 
(106; 137). This allele has also been associated with greater symptom severity in 
individuals with psychotic disorders (138; 139). However, in individuals with a 
psychotic disorder, Met homozygotes demonstrate increased psychotic reactivity to 
stress (140; 141). This does not fit with a model where reduced Met activity would be 
protective for individuals with a psychotic disorder – where we propose a deficit of 
cortical dopamine. This inconsistency may be due to the precise nature of the 
stressors under examination, or potentially due to gene-gene-environment 
interactions. 
 
Whilst glutamatergic and GABAergic alterations have been reported in neuroimaging 
studies of schizophrenia (124; 142), and the prodrome (143), the precise molecular 
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abnormalities remain to be determined in vivo. The links between glutamatergic 
dysregulation and dopaminergic signalling remain to be determined in schizophrenia 
(124), although there is some evidence of this in the prodrome (144).  
 
 
Conclusions 
Altered presynaptic striatal dopamine synthesis and release is consistently seen in 
schizophrenia. This is also seen to a lesser degree in the prodrome, and becomes 
worse as frank psychosis manifests. Blunted cortical dopamine release has now 
been demonstrated in schizophrenia, and there is increasing evidence that altered 
cortical function is linked to striatal dopamine hyperactivity in people with prodromal 
symptoms, indicating a central role for cortico-striatal dysregulation. Furthermore, it is 
now possible to begin to understand how genetic and environmental risk factors may 
lead to striatal dopamine dysregulation by impairing the cortical regulation of 
midbrain dopamine neurons. However, the precise molecular mechanisms remain to 
be fully elucidated, and blunted cortical dopamine release has yet to be investigated 
in the prodrome. Nevertheless, half a century on from the initial formulations of the 
dopamine hypothesis, it is possible to see what we need to do in order to rationally 
design medications that target the pathophysiology underlying the onset of the 
disorder to treat it, or indeed potentially prevent it. 
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Table 1:  PET studies of the dopaminergic system in individuals at increased clinical risk of 
schizophrenia 
 
↑: significantly higher in patient group; ↓: significantly lower level in patient group; -: no significant difference. [123I]IBZM: 
[123I](S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide; [11C]-+-PHNO: [11C]-(+)-4-propyl-9-
hydroxynaphthoxazine; [18F]- DOPA: 6-[18F]fluoro-L-Dihydroxyphenylalanine; DA: dopamine; MIST: Montreal Imaging Stress 
Task; D1, D2, D3: Dopamine receptor sub-type 1, 2 and 3 respectively; HC: healthy control; Scztyp: Schizotypal; UHR: Clincial high 
risk for psychosis.  
a
Synthesis capacity increased only in subgroup that transitioned to psychosis (n=9).  
b
 MIST leads to significant decrease in tracer binding in subgroup characterised as ‘potential schizotype’ on the basis that subjects 
scored >1.95 SD on the negative subscale of Chapman schizotypy questionnaire. 
Study Population Radiotracer Study type 
Region 
Reported 
Findings (standard 
effect size) 
 
Additional findings 
Bloemen et 
al. 2013(29)  
14 CHR  
15 HV 
[
123
I]IBZM 
Dopamine               
depletion 
Striatum 
 
 
-  
 
Positive correlation 
between D2/3 
receptor occupancy 
by dopamine and 
positive CHR 
symptoms 
Howes et al. 
2009 (30) 
24 CHR 
12 HV 
[
18
F]-DOPA 
Dopamine 
synthesis 
capacity 
Striatum ⬆ (0.75) 
 
Howes et al. 
2011b(32) 
a
  
30 CHR  
29 HV 
[
18
F]-DOPA 
Dopamine 
synthesis 
capacity 
Striatum ⬆(1.18)a 
No change in 
CHR subjects 
who did not 
convert to 
psychosis 
Mizrahi  et 
al. 2012(28) 
12 CHR 
12 HV 
[
11
C]-+-
PHNO 
MIST 
induced 
dopamine 
release 
Striatum ⬆(0.98) 
 
Suridjan et 
al. 2013 (27) 
12 CHR 
12 HV 
[
11
C]-+-
PHNO 
D2
high
/D3 
receptor 
availability 
Striatum, 
thalamus, 
globus 
pallidus, 
substantia 
nigra 
- 
 
Abi-
dargham  et 
al. 
2004(146) 
13 Scztyp 
13 HV 
[
123
I]IBZM 
Amphetamine 
induced 
dopamine 
release 
Striatum ⬆ (0.93) 
 
Soliman et 
al. 
2008(76)
b
 
16 Scztyp 
10 HV 
[
11
C] 
raclopride 
MIST  
induced 
dopamine 
release 
Ventral 
striatum 
⬆ 
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Table 2:  PET studies of the dopaminergic system in individuals at increased genetic risk of 
schizophrenia 
 
2DG: 2-Deoxy-D-glucose; DA: dopamine; DZ: Dizygotic; GHR: Genetic high risk; mPFC: Medial prefrontal cortex; MZ: monozygotic; 
STG: superior temporal gyrus. 
 
 
Study 
Population 
 
Phenotype Radiotracer Study type Region Reported 
Change in 
genetic high 
risk group 
(standard 
effect size) 
Brunelin 
et al. 2010 
(147) 
8 GHR 
10 HV 
Siblings of 
patients with 
schizophrenia 
[
11
C]raclopride 
2DG induced 
dopamine 
release 
Whole striatum. 
GHR show greater 
asymmetry between L/R 
striatum. No differences 
in DA release in ventral 
striatum 
↓ 
 
Huttunen  
et al. 2008 
(89) 
17 G
HR
 
17 HV 
1st degree 
relatives of 
patients with 
schizophrenia 
[
18
F]-DOPA 
Dopamine 
synthesis 
capacity 
Caudate and putamen 
No differences 
observed in ventral 
striatum 
⬆ 
Shotbolt  
et al. 2011 
(88) 
6 GHR 
20 HV 
Co-twins of 
patients with 
schizophrenia 
[
18
F]-DOPA 
Dopamine 
synthesis 
capacity 
Whole striatum - 
Hirvonen 
et al. 2005 
(91) 
6 MZ, 5 
DZ, 14 HV 
Co-twins of 
patients with 
schizophrenia 
[
11
C]raclopride 
D2/3 receptor 
density 
Caudate 
No differences 
observed in putamen or 
thalamus 
⬆ (0.85) 
Hirvonen 
et al. 
2006a 
(90) 
6 MZ, 5 
DZ, 13  
HV 
Co-twins of 
patients with 
schizophrenia 
[11C]SCH 
23390 
D1 receptor 
density 
mPFC, STG and 
angular gyrus 
⬆  
Hirvonen 
et al. 
2006b 
(148) 
6 MZ, 5 
DZ, 13  
HV 
Co-Twins of 
patients with 
schizophrenia 
[11C]SCH 
23390, 
[
11
C]raclopride 
D1:D2/3 ratio Caudate and putamen - 
Lee et al. 
2008 (92) 
11 GHR 
11 HV 
1
st
 and 2
nd
 
degree  
relatives of 
patients with 
schizophrenia 
[
11
C]raclopride 
Striatal D2/3 
receptor 
density 
Caudate and putamen. 
GHR show ↓ asymmetry 
of receptor density in 
putamen 
- 
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Study Population Radiotracer Findings 
Nagano-Saito 
et al., 2013 
(67) 
 11 HV 
 
[18F]-Fallypride  
MIST 
Stress induces displacement in dmPFC, vmPFC, PCG 
(15.87%), thalamus, L caudate, R putamen. No 
displacement observed in amygdala or ventral striatum 
Lataster et 
al., 2011 (66) 
12 HV. [18F]-Fallypride  
MIST 
Stress induces displacement in PFC. vmPFC DA release 
associated with subjectively rated stress. Extent of cortical 
release correlates with childhood adversity (68). 
Hernaus et 
al., 2015b 
(71) 
12 HV. 12 
NAPD 
[18F]-Fallypride  
MIST 
NAPD show non-significantly ↓ stress induced displacement 
in mPFC (d=0.31).  
Lataster et 
al., 2014 (69) 
11 HV. 14 
relatives 
[18F]-Fallypride  
MIST 
Relatives show ↓ proportion of voxels with displacement in 
mPFC (non significant. d=0.46). Relatives showed 
association between increased stress and decreased 
displacement (controls showed opposite). 
Mizrahi et al., 
2012(28) 
10 FEP 
12 HV 
12 CHR 
PHNO 
MIST 
DA release greatest for FEP, then CHR (in assoc striatum). 
No increased release for HV. Whole–striatum - CHR>HV (d 
= 0.98). Limbic striatum (0.65). 
Pruessner et 
al., 2004 (73) 
5 
Childhood 
hi-stress 
5 
Childhood 
low-stress 
Raclopride 
MIST 
Childhood high stress group show significantly ⬆ventral 
striatal displacement compared to low stress group. 
Oswald et al., 
2014 (74) 
28 HV Raclopride 
AMPH 
challenge 
Past traumatic events and perceived stress associated with 
greater ventral striatal DA release 
Egerton et 
al., 2016 (72) 
20 HV 
47 CHR 
[
18
F]-DOPA Physical and sexual abuse, and unstable family 
arrangements associated with increased dopamine 
synthesis capacity. 
 
 
Table 3:  PET studies of the effects of acute and chronic stress on the dopaminergic system 
 
CHR- Clinical High Risk; DA – dopamine; dmPFC – dorsomedial prefrontal cortex; FEP – First episode psychosis; HV – Healthy 
Volunteer; MIST – Montreal Imaging Stress Task; mPFC – medial prefrontal cortex; NAPD – non affective psychotic disorder; PCG 
– precentral gyrus; vmPFC – ventromedial prefrontal cortex 
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Gene Function Relationship to dopamine, stress and schizophrenia 
Akt1 
Akt 3 
Serine threonine kinases 
involved in post synaptic 
dopaminergic 
neurotransmission. 
Changes in post synaptic signal transduction could lead to 
hypersensitivity to dopamine and alter presynaptic feedback. 
AKT1 has been linked to Scz in two studies (82; 83). While AKT3 
has been implicated in GWAS. 
BDNF A neurotrophin that 
encourages the survival, 
growth and differentiation 
of neurons. 
Met carriers show greater striatal DA release in the context of a 
pain stressor, and has been associate with greater stress induced 
paranoia. 
COMT Catabolises dopamine 
(particularly cortical). Met 
allele associated with 
reduced catabolic activity. 
Met allele has been linked to reduced stress induced cortical DA 
release. Chronic stress has been associated with greater 
reductions in hippocampal volume in  Met homozygotes. 
DISC1 Participates in a wide 
range of cell functions. 
Involved in regulation 
presynaptic dopaminergic 
function. Also involved in 
anchoring PDE4A to 
spine apparatus. 
Animal models demonstrate DIC1 alterations can impair 
development of mesocortical DA neurons and lead to increased 
AMPH induced striatal DA release. Adolescent stress has been 
shown to lead to behaviour abnormalities only in mice with DISC1 
mutations.  Linked to Scz in multiple studies. 
DRD2 Dopamine receptor 2 Changes in pre and postsynaptic receptor density or function may 
have marked effects on dopaminergic signalling. SNP has been 
associated with greater stress induced DA release. Animal study 
demonstrated a certain SNP is associated with increased D2R 
density in the nucleus accumbens following maternal deprivation. 
Locus associated in schizophrenia GWAS. 
PDE4A Involved in in a variety of 
responses to extracellular 
signals. 
Together with DISC1 involved in modulation of stress signalling 
pathways, impairment leads to disinhibition of the stress response 
and PFC impairment. Has been linked to schizophrenia. 
 
 
Table 4: Genes related to dopaminergic functioning, schizophrenia and stress
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Figure 1. The regulation of mesostriatal dopaminergic function by cortical glutamatergic 
projections and GABAergic interneurons 
Figure 2. Model integrating genetic and environmental factors, dopaminergic dysregulation and 
the development of psychotic symptoms (DA=dopamine) 
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